Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients? A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

Study ID	Sample size	Gender (men%)	Mean age (years)	Diagnostic criteria	Randomization method	Blinding method	Intervention		Course (d)	Follow-up time (d)	Outcome indicators
	T/C	T/C	T/C				C	T
Song et al. [12]	334/341	67.1/68.6	58.7/58.1	America 2007 [10]	Interactive web response system	Double blinded	BT	BT + XBJ 100 ml bid	7	28	2, 3, 4, 11
Jing [13]	30/30	60.0/66.7	61.5/62.1	America 2007	Allocation sequence, assigned random number by system	Double blinded	BT	BT + XBJ 100 ml bid	7	28	2, 5, 11
Liu [14]	29/35	65.5/60.0	71.8/77.7	China 2016 [8]	Random number table	Unstated	BT	BT + XBJ 50 ml bid	7	—	1, 6, 7, 8, 9
Wang [15]	34/34	64.7/58.8	75.2/75.6	China 2016	Random number table	Unstated	BT (Biapenem 0.3 g q8 h)	BT + XBJ 50 ml bid	7	—	1, 6, 11
Wang et al. 2019 [16]	49/49	57.1/61.2	54.8/53.3	China 2016	Draw method	Unstated	BT (Cefoperazone sulbactam 3.0 g q12 h + Levofloxacin 0.5 g qd)	BT + XBJ 50 ml bid	7	—	1, 3, 4, 11
Yang and Xu [17]	98/98	63.3/66.3	57.4/53.6	America 2007	Random number table	Unstated	BT	BT + XBJ 50 ml bid	7	—	1
Kong [18]	34/34	82.4/85.3	48.9/50.6	America 2007	Interactive web response system	Double blinded	BT	BT + XBJ 50 ml bid	7	—	1, 5, 6, 7
Cheng et al. [19]	40/40	62.5/52.5	—	America 2001 [11]	Unstated	Unstated	BT	BT + XBJ 50 ml bid	7	—	1, 5, 7
Lu [20]	23/23	65.2/60.9	71.04/69.3	America 2001	Unstated	Unstated	BT	BT + XBJ 50 ml bid	7	—	1, 6, 7, 11
Yu and Ma [21]	30/30	76.7/70.0	52.1/54.5	China 2006 [9]	Unstated	Unstated	BT	BT + XBJ 100 ml bid	7	28	1, 2, 8, 9
Yu [22]	38/38	57.9/52.6	65.9/67.1	America 2007	Unstated	Unstated	BT	BT + XBJ 100 ml bid	7	—	1, 5, 7
Che et al. [23]	60/60	—	—	America 2007	Random number table	Unstated	BT	BT + XBJ 100 ml bid	7	—	1, 5, 6
Fu and Ge [24]	34/34	70.6/64.7	69.6/67.8	America 2001	Unstated	Unstated	BT	BT + XBJ 100 ml bid	7	—	1, 5, 7
Sheng et al. [25]	21/21	81.0/61.9	43.6/44.3	China 2016	Unstated	Unstated	BT	BT + XBJ 50 ml bid	7	28	2, 3, 6
Zhu and Liu [26]	22/21	72.7/66.7	68.3/64.6	America 2007	Random number table	Unstated	BT	BT + XBJ 100 ml bid	7	28	2, 3, 4
Gong et al. [27]	16/14	56.3/78.6	57.0/59.0	China 2006	Random number table	Unstated	BT	BT + XBJ 100 ml bid	7	—	5, 6, 8
Ji [28]	19/21	—	—	China 2006	Unstated	Unstated	BT	BT + XBJ 100 ml bid	7	—	3, 4
Yao et al. [29]	23/23	73.9/65.2	45.6/44.8	America 2007	Unstated	Unstated	BT	BT + XBJ 100 ml bid	7	—	4, 8, 9
Diao et al. [30]	50/50	—	—	America 2007	Random number table	Unstated	BT	BT + XBJ 50 ml bid	7	—	5, 7, 8, 9
Wang et al. [31]	16/16	—	—	America 2001	Random number table	Unstated	BT	BT + XBJ 50 ml bid	7	—	5, 7
Du [32]	30/30	60.0/53.3	58.6/57.9	America 2007	Random number table	Unstated	BT	BT + XBJ 50 ml bid	7	—	8

Note. T: intervention group; C: control group; BT: basic treatment including rational antibiotic treatment, early fluid resuscitation, mechanical ventilation, use of glucocorticoids, nutrition support, maintenance of homeostatic equilibrium, and other comprehensive therapies. Outcome indicators: 1, effective rate; 2, 28-day mortality; 3, ICU stay time; 4, duration of mechanical ventilation; 5, CRP; 6, PCT; 7, WBC; 8, TNF-α; 9, IL-6; 10, D-dimer; 11, adverse reactions.